MicroRNA response to environmental mutagens in liver

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 717, Issue 1-2, 2011, Pages 67-76

  Elamin, Bahaeldin K ^a,b   Callegari, Elisa ^a   Gramantieri, Laura ^c   Sabbioni, Silvia ^a   Negrini, Massimo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Environmental cancer risk factors; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; MicroRNA

Indexed keywords

AFLATOXIN B1; ALCOHOL; ARSENIC; BENZO[A]PYRENE; CYCLONITE; MICRORNA; MICRORNA 122; MICRORNA 199; MUTAGENIC AGENT; TOBACCO SMOKE; UNCLASSIFIED DRUG;

AIR POLLUTION; ALCOHOL CONSUMPTION; CANCER RISK; CHEMICAL CARCINOGENESIS; COMBUSTION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; UPREGULATION; VIRUS REPLICATION;

AFLATOXIN B1; ANIMALS; ARSENIC; BENZO(A)PYRENE; CARCINOMA, HEPATOCELLULAR; ENVIRONMENTAL POLLUTANTS; ETHANOL; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER NEOPLASMS; MICRORNAS; MUTAGENS; POISONS; RISK FACTORS; RODENTICIDES; TOBACCO; TRIAZINES;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; MAMMALIA;

EID: 82755197156     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.03.015     Document Type: Review

References (141)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-158.
3. Cullen B.R. Transcription and processing of human microRNA precursors. Mol. Cell 2004, 16:861-865.
4. Yi R., Qin Y., Macara I.G.B.R. Cullen exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17:3011-3016.
5. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., Zamore P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001, 293:834-838.
6. Ketting R.F., Fischer S.E., Bernstein E., Sijen T., Hannon G.J., Plasterk R.H. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001, 15:2654-2659.
7. Lai E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002, 30:363-364.
8. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
9. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
10. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
11. Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., Lim B., Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
12. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
13. Negrini M., Ferracin M., Sabbioni S., Croce C.M. MicroRNAs in human cancer: from research to therapy. J. Cell Sci. 2007, 120:1833-1840.
14. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136:26-36.
15. Cho W.C. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 2010, 1805:209-217.
16. Cho W.C. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42:1273-1281.
17. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
18. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 2007, 7:819-822.
19. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
20. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
21. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
22. Love T.M., Moffett H.F., Novina C.D. Not miR-ly small RNAs: big potential for microRNAs in therapy. J. Allergy Clin. Immunol. 2008, 121:309-319.
23. Stenvang J., Silahtaroglu A.N., Lindow M., Elmen J., Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol. 2008, 18:89-102.
24. Gramantieri L., Fornari F., Callegari E., Sabbioni S., Lanza G., Croce C.M., Bolondi L., Negrini M. MicroRNA involvement in hepatocellular carcinoma. J. Cell. Mol. Med. 2008, 12:2189-2204.
25. Varnholt H. The role of microRNAs in primary liver cancer. Ann. Hepatol. 2008, 7:104-113.
26. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
27. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., Jacob S.T., Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99:671-678.
28. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi G.L., Croce C.M., Bolondi L., Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67:6092-6099.
29. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
30. Huang Y.S., Dai Y., Yu X.F., Bao S.Y., Yin Y.B., Tang M., Hu C.X. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J. Gastroenterol. Hepatol. 2008, 23:87-94.
31. Wang Y., Lee A.T., Ma J.Z., Wang J., Ren J., Yang Y., Tantoso E., Li K.B., Ooi L.L., Tan P., Lee C.G. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J. Biol. Chem. 2008, 283:13205-13215.
32. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
33. Varnholt H., Drebber U., Schulze F., Wedemeyer I., Schirmacher P., Dienes H.P., Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
34. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
35. Yamamoto Y., Kosaka N., Tanaka M., Koizumi F., Kanai Y., Mizutani T., Murakami Y., Kuroda M., Miyajima A., Kato T., Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14:529-538.
36. Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., Zhuang S.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69:1135-1142.
37. Wong Q.W., Ching A.K., Chan A.W., Choy K.W., To K.F., Lai P.B., Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res. 2010, 16:867-875.
38. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., Watts L., Booten S.L., Graham M., McKay R., Subramaniam A., Propp S., Lollo B.A., Freier S., Bennett C.F., Bhanot S., Monia B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
39. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
40. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
41. Girard M., Jacquemin E., Munnich A., Lyonnet S., Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 2008, 48:648-656.
42. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
43. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., Lin C.D., Liao Y.L., Wang J.L., Chau Y.P., Hsu M.T., Hsiao M., Huang H.D., Tsou A.P. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.
44. Fornari F., Gramantieri L., Giovannini C., Veronese A., Ferracin M., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Tavolari S., Chieco P., Negrini M., Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009, 69:5761-5767.
45. Lin C.J., Gong H.Y., Tseng H.C., Wang W.L., Wu J.L. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 375:315-320.
46. Henke J.I., Goergen D., Zheng J., Song Y., Schuttler C.G., Fehr C., Junemann C., Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008, 27:3300-3310.
47. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
48. Pfeffer S., Baumert T.F. Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. J. Hepatol. 2009, 51:606-609.
49. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
50. Shan Y., Zheng J., Lambrecht R.W., Bonkovsky H.L. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007, 133:1166-1174.
51. Qiu L., Fan H., Jin W., Zhao B., Wang Y., Ju Y., Chen L., Chen Y., Duan Z., Meng S. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem. Biophys. Res. Commun. 2010, 398:771-777.
52. Kim S., Lee U.J., Kim M.N., Lee E.J., Kim J.Y., Lee M.Y., Choung S., Kim Y.J., Choi Y.C. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 2008, 283:18158-18166.
53. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70:5184-5193.
54. Ford C.E., Lau S.K., Zhu C.Q., Andersson T., Tsao M.S., Vogel W.F. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br. J. Cancer 2007, 96:808-814.
55. Johnson J.D., Edman J.C., Rutter W.J. A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10891.
56. Laval S., Butler R., Shelling A.N., Hanby A.M., Poulsom R., Ganesan T.S. Isolation and characterization of an epithelial-specific receptor tyrosine kinase from an ovarian cancer cell line. Cell Growth Differ. 1994, 5:1173-1183.
57. Park H.S., Kim K.R., Lee H.J., Choi H.N., Kim D.K., Kim B.T., Moon W.S. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol. Rep. 2007, 18:1435-1441.
58. Vogel W.F., Aszodi A., Alves F., Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol. Cell. Biol. 2001, 21:2906-2917.
59. Shen Q., Cicinnati V.R., Zhang X., Iacob S., Weber F., Sotiropoulos G.C., Radtke A., Lu M., Paul A., Gerken G., Beckebaum S. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol. Cancer 2010, 9:227.
60. Li J., French B., Wu Y., Vanketesh R., Montgomery R., Bardag-Gorce F., Kitto J., French S.W. Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease. Exp. Mol. Pathol. 2004, 77:184-192.
61. Yeligar S., Tsukamoto H., Kalra V.K. Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J. Immunol. 2009, 183:5232-5243.
62. Honda M., Rijnbrand R., Abell G., Kim D., Lemon S.M. Natural variation in translational activities of the 5' nontranslated RNAs of hepatitis C virus genotypes 1a and 1b: evidence for a long-range RNA-RNA interaction outside of the internal ribosomal entry site. J. Virol. 1999, 73:4941-4951.
63. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 2009, 50:453-460.
64. Zhang G.L., Li Y.X., Zheng S.Q., Liu M., Li X., Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010.
65. Ogimoto I., Shibata A., Kurozawa Y., Nose T., Yoshimura T., Suzuki H., Iwai N., Sakata R., Fujita Y., Ichikawa S., Fukuda K., Tamakoshi A. Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data. Kurume Med. J. 2004, 51:59-70.
66. Kuper H., Tzonou A., Kaklamani E., Hsieh C.C., Lagiou P., Adami H.O., Trichopoulos D., Stuver S.O. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int. J. Cancer 2000, 85:498-502.
67. Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Bouvard V., Altieri A., Cogliano V. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007, 8:292-293.
68. IARC Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 2002, 82:171-300.
69. Wild C.P. Environmental exposure measurement in cancer epidemiology. Mutagenesis 2009, 24:117-125.
70. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L.E., Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4402-4407.
71. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
72. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001, 37(Suppl. 8):S4-66.
73. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
74. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
75. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., London W.T. Eight-year follow-up of the 90 000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol. Biomarkers Prev. 2002, 11:369-376.
76. Franceschi S., Montella M., Polesel J., La Vecchia C., Crispo A., Dal Maso L., Casarin P., Izzo F., Tommasi L.G., Chemin I., Trepo C., Crovatto M., Talamini R. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol. Biomarkers Prev. 2006, 15:683-689.
77. IARC Hepatitis viruses. IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 59:1-255.
78. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11:97-107.
79. El-Serag H.B., Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch. Intern. Med. 2000, 160:3227-3230.
80. Chisari F.V. Unscrambling hepatitis C virus-host interactions. Nature 2005, 436:930-932.
81. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-29.
82. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
83. Ura S., Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., Sunakozaka H., Sakai Y., Horimoto K., Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
84. Liu Y., Zhao J.J., Wang C.M., Li M.Y., Han P., Wang L., Cheng Y.Q., Zoulim F., Ma X., Xu D.P. Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. Chin. Med. J. (Engl.) 2009, 122:10-14.
85. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.
86. Braconi C., Valeri N., Gasparini P., Huang N., Taccioli C., Nuovo G., Suzuki T., Croce C.M., Patel T. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16:957-966.
87. Marquez R.T., Bandyopadhyay S., Wendlandt E.B., Keck K., Hoffer B.A., Icardi M.S., Christensen R.N., Schmidt W.N., McCaffrey A.P. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab. Invest. 2010.
88. Randall G., Panis M., Cooper J.D., Tellinghuisen T.L., Sukhodolets K.E., Pfeffer S., Landthaler M., Landgraf P., Kan S., Lindenbach B.D., Chien M., Weir D.B., Russo J.J., Ju J., Brownstein M.J., Sheridan R., Sander C., Zavolan M., Tuschl T., Rice C.M. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12884-12889.
89. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
90. Donato F., Tagger A., Gelatti U., Parrinello G., Boffetta P., Albertini A., Decarli A., Trevisi P., Ribero M.L., Martelli C., Porru S., Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol. 2002, 155:323-331.
91. Avissar M., McClean M.D., Kelsey K.T., Marsit C.J. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 2009, 30:2059-2063.
92. Dolganiuc A., Petrasek J., Kodys K., Catalano D., Mandrekar P., Velayudham A., Szabo G. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin. Exp. Res. 2009, 33:1704-1710.
93. Mukaiya M., Nishi M., Miyake H., Hirata K. Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 1998, 45:2328-2332.
94. La Vecchia C., Negri E., Decarli A., D'Avanzo B., Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int. J. Cancer 1988, 42:872-876.
95. Tanaka K., Hirohata T., Takeshita S., Hirohata I., Koga S., Sugimachi K., Kanematsu T., Ohryohji F., Ishibashi H. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka Japan. Int. J. Cancer 1992, 51:509-514.
96. Hadziyannis S., Tabor E., Kaklamani E., Tzonou A., Stuver S., Tassopoulos N., Mueller N., Trichopoulos D. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int. J. Cancer 1995, 60:627-631.
97. Trichopoulos D., Day N.E., Kaklamani E., Tzonou A., Munoz N., Zavitsanos X., Koumantaki Y., Trichopoulou A. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int. J. Cancer 1987, 39:45-49.
98. Tanaka K., Hirohata T., Fukuda K., Shibata A., Tsukuma H., Hiyama T. Risk factors for hepatocellular carcinoma among Japanese women. Cancer Causes Control 1995, 6:91-98.
99. Yu M.C., Tong M.J., Govindarajan S., Henderson B.E. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County California. J. Natl. Cancer Inst. 1991, 83:1820-1826.
100. IARC Tobacco smoke and involuntary smoking. IARC Monogr. Eval. Carcinog. Risks Hum. 2004, 83:1-1438.
101. Izzotti A., Larghero P., Cartiglia C., Longobardi M., Pfeffer U., Steele V.E., De S. Flora Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung. Carcinogenesis 2010, 31:894-901.
102. Bennett J.W., Klich M. Mycotoxins. Clin. Microbiol. Rev. 2003, 16:497-516.
103. Groopman J.D., Scholl P., Wang J.S. Epidemiology of human aflatoxin exposures and their relationship to liver cancer. Prog. Clin. Biol. Res. 1996, 395:211-222.
104. Qian G.S., Ross R.K., Yu M.C., Yuan J.M., Gao Y.T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 1994, 3:3-10.
105. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
106. Yu M.C., Yuan J.M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004, 127:S72-78.
107. Ming L., Thorgeirsson S.S., Gail M.H., Lu P., Harris C.C., Wang N., Shao Y., Wu Z., Liu G., Wang X., Sun Z. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36:1214-1220.
108. Turner P.C., Sylla A., Diallo M.S., Castegnaro J.J., Hall A.J., Wild C.P. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J. Gastroenterol. Hepatol. 2002, 17(Suppl.):S441-448.
109. Hainaut P., Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008, 371:367-368.
110. Kensler T.W., Qian G.S., Chen J.G., Groopman J.D. Translational strategies for cancer prevention in liver. Nat. Rev. Cancer 2003, 3:321-329.
111. Smela M.E., Currier S.S., Bailey E.A., Essigmann J.M. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001, 22:535-545.
112. Wild C.P., Turner P.C. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002, 17:471-481.
113. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
114. Tao Chen R.H.H., Moore Martha M., Mei N. Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. Environ. Mol. Mutagen. 2010, 51:156-163.
115. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
116. McGlynn K.A., Rosvold E.A., Lustbader E.D., Hu Y., Clapper M.L., Zhou T., Wild C.P., Xia X.L., Baffoe-Bonnie A., Ofori-Adjei D., et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2384-2387.
117. McGlynn K.A., Hunter K., LeVoyer T., Roush J., Wise P., Michielli R.A., Shen F.M., Evans A.A., London W.T., Buetow K.H. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res. 2003, 63:4594-4601.
118. IARC IARC Monographs World Health Organization, vol. 7 1987, IARC Scientific Publications, pp. 100-106.
119. NRC Arsenic in Drinking Water 1999, National Academy Press, Washington, DC, p. 310.
120. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 1999, 107:359-365.
121. Waalkes M.P., Ward J.M., Liu J., Diwan B.A. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol. Appl. Pharmacol. 2003, 186:7-17.
122. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10907-10912.
123. Chen H., Li S., Liu J., Diwan B.A., Barrett J.C., Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004, 25:1779-1786.
124. Waalkes M.P., Liu J., Chen H., Xie Y., Achanzar W.E., Zhou Y.S., Cheng M.L., Diwan B.A. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J. Natl. Cancer Inst. 2004, 96:466-474.
125. Lu T., Liu J., LeCluyse E.L., Zhou Y.S., Cheng M.L., Waalkes M.P. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol. Sci. 2001, 59:185-192.
126. Marsit C.J., Eddy K., Kelsey K.T. MicroRNA responses to cellular stress. Cancer Res. 2006, 66:10843-10848.
127. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Giovannini C., Croce C.M., Bolondi L., Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
128. Myler C.A., Sisk W. Bioremediation of explosives contaminated soils (scientific questions/engineering realities). Environmental Bio/technology for Waste Treatment 1991, 137-146. Plenum Press, New York, NY. R.F.G.S. Sayler, J.W. Blackburn (Eds.).
129. Hawari J. Biodegradation of RDX and HMX: from basic research to field application. Biodegradation of nitroaromatic compounds and explosives 2000, 277-310. CRC Press, Boca Raton, FL. J.B.H.J.C. Spain, H.-J. Knackmuss (Eds.).
130. Burdette L.J., Cook L.L., Dyer R.S. Convulsant properties of cyclotrimethylenetrinitramine (RDX): spontaneous audiogenic, and amygdaloid kindled seizure activity. Toxicol. Appl. Pharmacol. 1988, 92:436-444.
131. Pan X., San Francisco M.J., Lee C., Ochoa K.M., Xu X., Liu J., Zhang B., Cox S.B., Cobb G.P. Examination of the mutagenicity of RDX and its N-nitroso metabolites using the Salmonella reverse mutation assay. Mutat. Res. 2007, 629:64-69.
132. Testud F., Glanclaude J.M., Descotes J. Acute hexogen poisoning after occupational exposure. J. Toxicol. Clin. Toxicol. 1996, 34:109-111.
133. Zhang B., Pan X. RDX induces aberrant expression of microRNAs in mouse brain and liver. Environ. Health Perspect. 2009, 117:231-240.
134. Hattemer-Frey H.A., Travis C.C. Benzo-a-pyrene: environmental partitioning and human exposure. Toxicol. Ind. Health 1991, 7:141-157.
135. Shen Y.L., Jiang Y.G., Greenlee A.R., Zhou L.L., Liu L.H. MicroRNA expression profiles and miR-10a target in anti-benzo[a] pyrene-7,8-diol-9,10-epoxide-transformed human 16HBE cells. Biomed. Environ. Sci. 2009, 22:14-21.
136. Yauk C.L., Jackson K., Malowany M., Williams A. Lack of change in microRNA expression in adult mouse liver following treatment with benzo(a)pyrene despite robust mRNA transcriptional response. Mutat. Res. 2011, 722:131-139.
137. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
138. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Zen K., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
139. Pauley K.M., Satoh M., Chan A.L., Bubb M.R., Reeves W.H., Chan E.K. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res. Ther. 2008, 10:R101.
140. Wong C.C., Wong C.M., Tung E.K., Au S.L., Lee J.M., Poon R.T., Man K., Ng I.O. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 2011, 140:322-331.
141. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., Ambs S., Chen Y., Meltzer P.S., Croce C.M., Qin L.X., Man K., Lo C.M., Lee J., Ng I.O., Fan J., Tang Z.Y., Sun H.C., Wang X.W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361:1437-1447.